PMID- 20969970 OWN - NLM STAT- MEDLINE DCOM- 20110913 LR - 20211020 IS - 1523-6536 (Electronic) IS - 1083-8791 (Print) IS - 1083-8791 (Linking) VI - 17 IP - 6 DP - 2011 Jun TI - Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci. PG - 923-9 LID - 10.1016/j.bbmt.2010.10.017 [doi] AB - Most candidates for hematopoietic stem cell transplantation (HSCT) lack a human leukocyte antigen (HLA)-identical sibling donor. Some patients may have a related donor with whom they are mismatched at 1 antigen/allele. It is not known whether such a match is preferable to a matched unrelated donor (MUD). We evaluated the outcomes (survival, relapse, nonrelapse mortality [NRM]) of all 28 patients with a single HLA antigen/allele mismatch identified through high-resolution HLA typing at HLA-A, -B, -C, -DRB1, and -DQB1, and all 318 patients with myeloid malignancies who received transplants from a 10/10 MUD treated during the same period of time at a single institution. Overall, outcomes for patients treated from a 1-antigen/allele mismatch related donor were significantly worse than from a MUD, primarily because of increased NRM. Overall survival (OS) rates at 3 years for 1-antigen/allele mismatched related donor and MUD transplant recipients were 19% and 45% (P = .007), and NRM rates were 40% and 26% (P = .05), respectively. Patients with class I mismatches appeared to have poorer OS than did patients with class II mismatches. A higher incidence of graft rejection was identified in the mismatched related donor group (P = .02). These results indicate that transplant outcomes are better with a MUD than with a 1 antigen/allele-mismatched related donor. CI - Copyright (c) 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. FAU - Ciurea, Stefan O AU - Ciurea SO AD - Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. FAU - Saliba, Rima M AU - Saliba RM FAU - Rondon, Gabriela AU - Rondon G FAU - Patah, Poliana A AU - Patah PA FAU - Aung, Fleur AU - Aung F FAU - Cano, Pedro AU - Cano P FAU - Andersson, Borje S AU - Andersson BS FAU - Kebriaei, Partow AU - Kebriaei P FAU - Popat, Uday AU - Popat U FAU - Fernandez-Vina, Marcelo AU - Fernandez-Vina M FAU - Champlin, Richard E AU - Champlin RE FAU - de Lima, Marcos AU - de Lima M LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States PT - Journal Article DEP - 20101020 PL - United States TA - Biol Blood Marrow Transplant JT - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation JID - 9600628 RN - 0 (HLA Antigens) SB - IM MH - Alleles MH - Blood Donors MH - Female MH - Graft Rejection/immunology/prevention & control MH - Graft vs Host Disease/genetics/*immunology/mortality/pathology MH - HLA Antigens/genetics/*immunology MH - *Hematopoietic Stem Cell Transplantation MH - Histocompatibility MH - Histocompatibility Testing/*methods MH - Humans MH - Leukemia, Myeloid/genetics/*immunology/mortality/pathology/*therapy MH - Male MH - Middle Aged MH - Retrospective Studies MH - Risk Factors MH - Survival Analysis MH - Transplantation MH - Transplantation, Homologous MH - Treatment Outcome PMC - PMC4112359 MID - NIHMS601820 EDAT- 2010/10/26 06:00 MHDA- 2011/09/14 06:00 PMCR- 2014/07/28 CRDT- 2010/10/26 06:00 PHST- 2010/08/13 00:00 [received] PHST- 2010/10/13 00:00 [accepted] PHST- 2010/10/26 06:00 [entrez] PHST- 2010/10/26 06:00 [pubmed] PHST- 2011/09/14 06:00 [medline] PHST- 2014/07/28 00:00 [pmc-release] AID - S1083-8791(10)00455-6 [pii] AID - 10.1016/j.bbmt.2010.10.017 [doi] PST - ppublish SO - Biol Blood Marrow Transplant. 2011 Jun;17(6):923-9. doi: 10.1016/j.bbmt.2010.10.017. Epub 2010 Oct 20.